EP 183: Rewriting the Rules for Ultra-Rare Diseases with Kent Rogers of EveryONE Medicines

This week on The Genetics Podcast, Patrick is joined by Kent Rogers, Chief Executive Officer at EveryONE Medicines. They discuss Kent’s journey across every side of the desk in the drug discovery space, EveryONE Medicines’ efforts to develop antisense oligonucleotides for ultra-rare diseases, and the need to adapt regulatory models for n-of-1 therapies.Show Notes: 00:00 Intro to The Genetics Podcast00:59 Welcome to Kent and his experiences across every side of the pharma ‘desk’06:00 Challenges of commercialization for ultra-rare disease therapies and the advantage of antisense oligonucleotides (ASOs) 10:28 EveryONE Medicines’ approach to regulatory bodies12:30 Regulatory feedback and expectations from EveryONE Medicines’ platform-based approach to n-of-1 therapies15:47 Differences in regulatory requirements for rare disease across countries 19:53 Insights from being on different sides of the drug development industry22:40 Differences in healthcare systems across countries that can facilitate or impede drug development26:57 Rationale behind focusing on ASOs for treating rare diseases 28:03 Building EveryONE Medicines and Kent’s approach to leadership33:20 Lessons from Kent’s career37:17 Closing remarks Find out moreEveryONE Medicines (https://www.eomeds.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link